COMMUNIQUÉS West-GlobeNewswire

New LockeT Data Accepted in Leading Electrophysiology Journal
06/04/2026
FORT MILL, S.C., April 06, 2026 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (NYSE American: VTAK) (“VTAK” or the “Company”) today announced that the manuscript titled “Safety and Efficacy of LockeT Suture Retention [...]
Avalyn Appoints Jon Congleton, Seasoned Biopharmaceutical Executive, to its Board of Directors
06/04/2026
BOSTON, April 06, 2026 (GLOBE NEWSWIRE) -- Avalyn Pharma Inc., (“Avalyn” or the “Company”), a clinical-stage biopharmaceutical company pioneering inhaled therapies to transform the treatment paradigm of serious, rare [...]
Verrica Pharmaceuticals to Participate in the 25th Annual Needham Virtual Healthcare Conference
06/04/2026
WEST CHESTER, Pa., April 06, 2026 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a therapeutics company developing and commercializing medications for the treatment of dermatological [...]
Stablecoin Development Corporation Begins Trading on NYSE American Under Ticker “SDEV”
06/04/2026
Company Announces Completion of Corporate Name Change and Provides Updated SKY Holdings and Staking Metrics EMERYVILLE, Calif., April 06, 2026 (GLOBE NEWSWIRE) -- Stablecoin Development Corporation (NYSE American: SDEV [...]
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences
06/04/2026
FLORHAM PARK, N.J., April 06, 2026 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on commercializing and developing novel treatments for gastrointestinal (GI) [...]
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
06/04/2026
CLEVELAND, April 06, 2026 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awards were approved [...]
Scienture Provides Annual Shareholder Update, Outlining Significant Progress and Strategic Priorities for the Year Ahead
06/04/2026
COMMACK, NY, April 06, 2026 (GLOBE NEWSWIRE) -- SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) (“Scienture”) a holding company for existing and planned pharmaceutical operating companies focused on providing enhanced value to [...]
Geron to Participate in the 25th Annual Needham Virtual Healthcare Conference
06/04/2026
FOSTER CITY, Calif., April 06, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that [...]
Akari Therapeutics Announces Strategic Partnership with WuXi XDC to Advance Development of Its Novel ADC Payload Targeting RNA Splicing
06/04/2026
Strategic Partnership Enables Akari to Accelerate IND Filing By Late 2026 TAMPA, Fla. and LONDON, April 06, 2026 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), an oncology biotechnology company developing [...]
Aveanna Healthcare Announces Second Annual Aveanna Cares Month of Service
06/04/2026
ATLANTA, April 06, 2026 (GLOBE NEWSWIRE) -- Aveanna Healthcare (NASDAQ: AVAH ) today announced the second year of Aveanna Cares, the company’s month-long, team-based volunteer initiative dedicated to giving back to the [...]
Egg Medical présente EggNest™ Complete Flex : une protection sans tablier, sans travaux, sans interruption de service ni perturbation
06/04/2026
MINNEAPOLIS, 06 avr. 2026 (GLOBE NEWSWIRE) -- Egg Medical annonce le lancement d’EggNest™ Complete Flex, une avancée révolutionnaire en matière de protection contre les radiations qui permet aux cliniciens de travailler [...]
Axe Compute Names Kyle Okamoto President, Adding Deep Infrastructure Systems Expertise to Executive Team
06/04/2026
Okamoto, who helped scale Aethir's decentralized GPU network to 200+ global locations, will lead enterprise growth strategy and execution at Axe Compute PITTSBURGH, April 06, 2026 (GLOBE NEWSWIRE) -- Axe Compute (Nasdaq [...]
Stipple Bio Emerges From Stealth with Oversubscribed $100 Million Series A Financing to Advance STP-100 into Early Clinical Studies and Advance a Precision Oncology Pipeline that Leverages its Pointillist Platform
06/04/2026
– Series A financing co-led by RA Capital, a16z Bio+Health and Nextech Invest, and includes participation from existing investors Emerson Collective Investments (managed by Yosemite), GV (Google Ventures), LoLa Capital [...]
Profusa Expands into Multi-Billion Dollar Precision Diagnostics Market with $30M Letter of Intent for a PanOmics Platform
06/04/2026
Company secures scalable multi-omics diagnostics platform and launches Mayo Clinic partnership adding to Lumee real-time biochemistry monitoring platform to advance pancreatic cancer applications BERKELEY, CA, April 06 [...]
Agios to Host First Quarter 2026 Financial Results Conference Call and Webcast on April 29 at 8:00 a.m. ET
06/04/2026
CAMBRIDGE, Mass., April 06, 2026 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, [...]
BioCryst Appoints Sandeep M. Menon Chief Research and Development Officer
06/04/2026
— Experienced R&D leader with a track record of advancing innovative therapies from early development to global approval — RESEARCH TRIANGLE PARK, N.C., April 06, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, [...]
Immunocore to present at the 25th Annual Needham Virtual Healthcare Conference
06/04/2026
Immunocore to present at the 25th Annual Needham Virtual Healthcare Conference (OXFORDSHIRE, England & RADNOR, Penn. & GAITHERSBURG, Md., US, 06 April 2026) Immunocore Holdings plc (Nasdaq: IMCR) (“Immunocore” [...]
Opus Genetics Solidifies Leadership Position in Gene Therapy Development for Inherited Retinal Diseases with Strategic Long-Term Financing by Oberland Capital
06/04/2026
- Agreement includes up to $155 million in non-dilutive funding with an upfront payment of $35 million and a $5 million equity investment - - Strategic financing to accelerate development of earlier-stage gene therapy [...]
Praxis Precision Medicines Announces Positive Results from the EMBRAVE Part A Trial of Elsunersen in Patients with SCN2A Early-Onset Developmental and Epileptic Encephalopathy
06/04/2026
Elsunersen demonstrated placebo-adjusted seizure reduction from baseline of 77% (p=0.015) 71% of elsunersen-treated patients achieved >50% seizure reduction by period 6, with sustained benefit observed in the open- [...]

Pages